<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624866</url>
  </required_header>
  <id_info>
    <org_study_id>17200681</org_study_id>
    <nct_id>NCT05624866</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Triamcinolone Treatment in Carpal Tunnel Syndrome</brief_title>
  <official_title>Dexmedetomidine Versus Triamcinolone Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carpal tunnel syndrome (CTS) is a common mononeuropathy due to entrapment of the median nerve&#xD;
      in the carpal tunnel. a lot of modalities are available for treatment of mild to moderate&#xD;
      CTS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carpal tunnel syndrome (CTS) is a common mononeuropathy due to entrapment of the median nerve&#xD;
      in the carpal tunnel. a lot of modaleties are available for treatment of mild to moderate&#xD;
      CTS.&#xD;
&#xD;
      In case of failed conservative oral therapey, local hydro-dessction of the median nerve can&#xD;
      be done with saline alone. local anethetics, steroids, hyalase,and ozone have been utilized&#xD;
      to augment the symptoms reliefe.&#xD;
&#xD;
      Dexmeditomidine (DEX) has been studied as adjuvant for nerve block to aumnet the pain&#xD;
      reliefe. Recently, it has been discovered that DEX can offer some antinflammatory effects&#xD;
      when injected in the perineural area. Upon such discovery, the goal of this study has been&#xD;
      built.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2022</start_date>
  <completion_date type="Anticipated">July 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment Investigate if, and to what extent,carapl tunnel hydro-dissection using DEX or triamcinolone (TM) along with saline, under ultrasound guidance, can improve the clinical condition, change in nerve conduction parameters of patients with CTS and delay or avoid the surgical intervention.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain visual analoge scale visual analog scale of pain value of (0 cm) no pain , and value of (10 cm) worst pain</measure>
    <time_frame>6 months</time_frame>
    <description>visual analog scale of pain value of (0 cm) no pain , and value of (10 cm) worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of cross sectional area of the median nerve</measure>
    <time_frame>6 months</time_frame>
    <description>change of cross sectional area of the median nerve mm2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <arm_group>
    <arm_group_label>Dexmeditomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection</description>
    <arm_group_label>Dexmeditomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection</description>
    <arm_group_label>Triamcinolone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients&#xD;
&#xD;
          -  complaining of carpal tunnel syndrome of 3 month duration or more&#xD;
&#xD;
          -  diagnosed axonal neuropathy using electrodiagnosis , nerve conduction study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient refusal&#xD;
&#xD;
          -  infection at the site of intervention&#xD;
&#xD;
          -  allergy to utilized drugs&#xD;
&#xD;
          -  diabetic&#xD;
&#xD;
          -  previous surgery in the site of injection&#xD;
&#xD;
          -  previous injection in the targeted site within the last year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut Universit Hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad Said, Professor</last_name>
      <phone>01007046058</phone>
      <email>emadzarief@aun.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Rafeek Aziz, Assistant lecturer</last_name>
      <phone>01006018620</phone>
      <email>rafeek_aziz@med.aun.du.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 31, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Emad Zarief , MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

